23 Bladder Cancer Clinical Trials in Los Angeles, CA (2026)

Q: How do I join a clinical trial in Los Angeles?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you.

Recruiting Bladder Cancer Studies in Los Angeles

NCT02660645Recruiting

Blue Light Cystoscopy With Cysview® Registry

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices....

Los Angeles, CA4,400 participantsPhotocure

View Study Details

NCT03193541Recruiting

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic h...

Los Angeles, CA900 participantsCedars-Sinai Medical Center

View Study Details

NCT03547973Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC)....

Los Angeles, CAPHASE2827 participantsGilead Sciences

View Study Details

NCT06319820Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of ...

Los Angeles, CAPHASE3641 participantsJanssen Research & Development, LLC

View Study Details

NCT07129993Recruiting

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progre...

Los Angeles, CAPHASE2630 participantsDaiichi Sankyo

View Study Details

NCT06510374Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)...

Los Angeles, CAPHASE3454 participantsFerring Pharmaceuticals

View Study Details

NCT07218380Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugrati...

Los Angeles, CAPHASE3450 participantsEli Lilly and Company

View Study Details

NCT04564781Recruiting

Predicting BCG Response

To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) requ...

Los Angeles, CA400 participantsCedars-Sinai Medical Center

View Study Details

NCT04752722Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

Los Angeles, CAPHASE1350 participantsenGene, Inc.

View Study Details

NCT06567743Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer....

Los Angeles, CAPHASE2325 participantsCG Oncology, Inc.

View Study Details

NCT06833073Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread...

Los Angeles, CAPHASE2308 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03193515Recruiting

A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

Voided urinary cytology (VUC) is the most widely used urine-based assay for detecting bladder cancer (BCa); however, it fails to detect approximately 50% of low-grade or early stage BCa when it is mos...

Los Angeles, CA300 participantsCedars-Sinai Medical Center

View Study Details

NCT06545955Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...

Los Angeles, CAPHASE3250 participantsFerring Pharmaceuticals

View Study Details

NCT05316155Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose...

Los Angeles, CAPHASE1235 participantsJanssen Research & Development, LLC

View Study Details

NCT07217171Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment optio...

Los Angeles, CAPHASE1160 participantsEvolveImmune United, Inc

View Study Details

NCT06770582Recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-mu...

Los Angeles, CAPHASE2160 participantsNational Cancer Institute (NCI)

View Study Details

NCT05951179Recruiting

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1...

Los Angeles, CAPHASE2131 participantsProtara Therapeutics

View Study Details

NCT05521698Recruiting

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder ca...

Los Angeles, CAPHASE180 participantsUniversity of Wisconsin, Madison

View Study Details

NCT06534983Recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)

The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study parti...

Los Angeles, CAPHASE262 participantsHoffmann-La Roche

View Study Details

NCT04442724Recruiting

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor locati...

Los Angeles, CANA60 participantsCedars-Sinai Medical Center

View Study Details

NCT05483868Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser a...

Los Angeles, CAPHASE155 participantsAura Biosciences

View Study Details

NCT05775471Recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer....

Los Angeles, CAPHASE221 participantsJonsson Comprehensive Cancer Center

View Study Details

NCT06417190Recruiting

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or w...

Los Angeles, CAPHASE220 participantsLeslie Ballas

View Study Details

About Bladder Cancer Clinical Trials in Los Angeles

Bladder cancer occurs in the tissues of the bladder and is one of the most common cancers. It has a high recurrence rate, requiring ongoing monitoring. Treatments include surgery, intravesical therapy, chemotherapy, and immunotherapy.

There are currently 23 bladder cancer clinical trials recruiting participants in Los Angeles, CA. These studies are seeking a combined 11,219 participants. Research is being sponsored by Photocure, Cedars-Sinai Medical Center, Gilead Sciences and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Bladder Cancer Clinical Trials in Los Angeles — FAQ

Are there bladder cancer clinical trials in Los Angeles?

Yes, there are 23 bladder cancer clinical trials currently recruiting in Los Angeles, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What bladder cancer treatments are being tested?

The 23 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for bladder cancer.

Data updated July 16, 2026 from ClinicalTrials.gov